Disease
Atherosclerotic Cardiovascular Disease
Plaque-driven narrowing/hardening of the arteries and its clinical consequences -- coronary heart disease, stroke, and peripheral artery disease -- primarily driven by hyperlipidemia/dyslipidemia and managed with lipid-lowering and antiplatelet/anticoagulant therapy.
Total attributable cost
$381.0B
$19,145/patient
Drug spend
$22.7B
$1,139/patient
6% of total cost is drugs
All severities (2015-2018 NHANES cycle) · US